The small antibodies, which are nearly one-tenth the size of most alternative cancer delivery bio-markers, slip throughout solid tumors instead of piling up at the surface during the cancer treatment.
Nanovega president Marek Malecki said, ”With intellectual property protected [9 patents and applications] we look to scale up production of our unique synthetic antibodies."
Mentor Capital CEO Chester Billingsley said, "We are especially intrigued by Nanovega’s ability to tag cancer cells or fragments circulating in the blood with ultra-small metal atoms."
The metal nano-tags separate the cancer cells using a magnetic field, which are then grown and tested outside the body to predetermine effective chemotherapy to be prescribed.
The nano-bodies are already produced for multiple diagnostic and therapeutic applications by outside researchers.